U.S. markets open in 1 hour 44 minutes

Alterity Therapeutics Limited (ATHE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7702-0.0251 (-3.16%)
At close: 04:00PM EST
0.8500 +0.08 (+10.36%)
Pre-Market: 07:18AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close0.7953
Bid0.0000 x 1800
Ask0.0000 x 800
Day's Range0.7466 - 0.8000
52 Week Range0.6800 - 2.7500
Avg. Volume2,470,508
Market Cap31.701M
Beta (5Y Monthly)0.94
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ATHE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Alterity Therapeutics Limited
    Daily – Vickers Top Buyers & Sellers for 01/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    9 days agoArgus Research
View more
  • Benzinga

    Want to Buy Alterity Therapeutics (ATHE) Stock? See This First.

    Alterity Therapeutics was founded in Melbourne, Australia in 1997 under the name Prana Biotechnology. Focusing on treatments for neurodegenerative diseases, the firm hopes to disrupt current medical thought on these conditions, offering alternatives for patients with any prognosis. With offices in Melbourne and San Francisco, the company has been listed on the NASDAQ since 2002. Step 1: Open up a brokerage account. You must open a brokerage account when you are ready to buy and sell stocks. Whil

  • Simply Wall St.

    Alterity Therapeutics (ASX:ATH) Is In A Good Position To Deliver On Growth Plans

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Benzinga

    Alterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerative Disorder

    Alterity Therapeutics (NASDAQ: ATHE) has announced the presentation of expanded animal data to support the commercialization of its lead compound ATH434 in development to treat Parkinsonian disorders. Data were presented at the American Academy of Neurology virtual annual meeting. The data from an animal model of Multiple System Atrophy (MSA) independently confirm and extend previous findings demonstrating that ATH434 reduces α-synuclein pathology, preserves neurons, and improves motor function. MSA is a rare neurodegenerative disorder characterized by autonomic dysfunction, tremors, slow movement, muscle rigidity, and postural instability. The new data indicate that ATH434 preserves neurons not only in the substantia nigra, a main area of pathology in Parkinson's disease but also in the striatum, a region of the brain that integrates information from the cortex and substantia nigra to achieve fine motor control. The study also showed that ATH434 led to reductions in glial cell inclusions, comprised of aggregated α-synuclein, and levels of the toxic form of α-synuclein, both of which are pathological features of MSA. Price Action: ATHE shares are up 22.4% at $1.53 in premarket trading on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaBrii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B StudyTrevena's TRV027 Included In Global COVID-19 Study© 2021 Benzinga does not provide investment advice. All rights reserved.